Coeptis Therapeutics Inc

Coeptis Therapeutics — Investor Presentation (December 2023)

20 slides from Coeptis Therapeutics's investor presentation, Dec 5, 2023

  1. Slide 1: Coeptis Therapeutics Holdings, Inc. Corporate Overview

    Slide 1: Coeptis Therapeutics Holdings, Inc. Corporate Overview

    1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V5.0 December - 2023

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    2 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Coeptis made in connection with this Presentation, constitute “forw

  3. Slide 3: Important Legal Disclaimers

    Slide 3: Important Legal Disclaimers

    3 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Important Legal Disclaimers No Offer or Solicitation: This Presentation is for informational purposes and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Coeptis,

  4. Slide 4: Important Legal Disclaimers cont'd.

    Slide 4: Important Legal Disclaimers cont'd.

    4 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Important Legal Disclaimers cont’d. This Presentation is not a substitute for any other document that Coeptis may file with the SEC, and this Presentation is qua lif ied in its entirety by such SEC filings. Readers may obtain free copi

  5. Slide 5: Risk Factors

    Slide 5: Risk Factors

    5 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Risk Factors There are a number of risks related to us and our operations. You should carefully review the risks described in our filings th at we make with the SEC from time to time. If any of these risks actually occurs, our business

  6. Slide 6: Coeptis Therapeutics

    Slide 6: Coeptis Therapeutics

    6 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved COEPTIS THERAPEUTICS We are a Pittsburgh, PA based clinical stage biotechnology company founded by an experienced team developing innovative cell therapy platforms in oncology and other diseases .

  7. Slide 7: Coeptis Therapeutics Highlights

    Slide 7: Coeptis Therapeutics Highlights

    7 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved 5 Dev and Clinical Collaborations • University of Pittsburgh • Karolinska Institute • Fred Hutch Cancer Research Center • Duke Cancer Institute • Novant Health 2 Clinical Studies • DVX - 201 for Patients with Relapsed/ Refractory AML a

  8. Slide 8: Corporate Milestones

    Slide 8: Corporate Milestones

    8 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Corporate Milestones 2021 Secured ownership rights to GEAR from VyGen - Bio 2022 IPO listed on NASDAQ (COEP) 2023 Expanded SNAP - CAR License 2022 License SNAP - CAR from University of Pittsburgh 2023 Licensed DVX - 201 clinical progra

  9. Slide 9: Diverse Pipeline

    Slide 9: Diverse Pipeline

    9 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Diverse Pipeline PHASE 2 PHASE 1 PRE - CLINICAL TARGET INDICATION PROGRAM Relapsed/Refractory Acute Myeloid Leukemia & High Risk MDS DVX201 - AML - 01 ( Allo ) Acute Viral Respiratory Diseases DVX201 - COV - 01 ( Allo ) Multiple Myelom

  10. Slide 10: Proprietary Allogeneic Immune Effector Cell Generation Platform

    Slide 10: Proprietary Allogeneic Immune Effector Cell Generation Platform

    10 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Proprietary Allogeneic Immune Effector Cell Generation Platform • FDA - regulated cord blood as source material • Established pooled donor manufacturing and cryopreservation (2 FDA approved INDs fo r NK cell product, DVX201 ) • Reprod

  11. Slide 11: DVX-201: Phase Clinical Trials of a First-in-Human Pooled Donor Unmodified NK Cell Product

    Slide 11: DVX-201: Phase Clinical Trials of a First-in-Human Pooled Donor Unmodified NK Cell Product

    11 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved DVX - 201: Phase 1 Clinical Trials of a First - in - Human Pooled Donor Unmodified NK Cell Product • Indication 1 : COVID Pneumonia (NCT04900454), Cell Therapy in Subjects Hospitalized for COVID - 19 • Dosing : Single dose, MTD study;

  12. Slide 12: SNAP-CAR: A Universal CAR Platform

    Slide 12: SNAP-CAR: A Universal CAR Platform

    12 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Proprietary Platform Technology: A monoclonal antibody conjugated (tagged) to a benzyl guanine linker which is specifically recognized by the custom SNAP - CAR effector cells Potential to generate a variety of SNAP - CAR effector cell

  13. Slide 13: Treatment Approach

    Slide 13: Treatment Approach

    13 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Patient presents with cancer Universal SNAP - CAR Effector Cell Infusion The oncologist selects tagged anti - tumor antibody( ies ) to address specific malignancy Treatment Approach 1 2 3

  14. Slide 14: Ability to Target Both Heme Malignancies and Solid Tumors with a Single Bank of SNAP-CAR-ECs

    Slide 14: Ability to Target Both Heme Malignancies and Solid Tumors with a Single Bank of SNAP-CAR-ECs

    14 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Ability to Target Both Heme Malignancies and Solid Tumors with a Single Bank of SNAP - CAR - ECs Hematological Malignancies Solid Tumors TBD TBD TUMOR MICROENVORNMENT CANCER CELL Examples Only

  15. Slide 15: Specific SNAP-CAR Opportunities

    Slide 15: Specific SNAP-CAR Opportunities

    15 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Specific SNAP - CAR Opportunities Effector Cell (EC) (NK, ⍺ β - T, ߛ ߜ - T, Macrophages) SNAP - CAR gene insertion UNIVERSAL SNAP - CAR EC Multiple Myeloma B - cells Malignancies Solid Tumors CD19, CD20, CD22, TBD CD123, CD33, CLC12A,

  16. Slide 16: CD38-GEAR-NK Cells (Gene Edited Antibody Resistant)

    Slide 16: CD38-GEAR-NK Cells (Gene Edited Antibody Resistant)

    16 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the over

  17. Slide 17: Current Anti-CD38 Pathway vs Pathway with GEAR-NK Cell Therapy

    Slide 17: Current Anti-CD38 Pathway vs Pathway with GEAR-NK Cell Therapy

    17 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Animations herein are provided as visual aids to help articulate hypothesized proof - of - concept in a general manner and do not de pict precise scientific mechanisms - of - action. Anti - CD38 mAbs (Infused antibodies from current c

  18. Slide 18: Coeptis Management Team

    Slide 18: Coeptis Management Team

    18 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved COEPTIS MANAGEMENT TEAM Dave Mehalick Co - Founder, President & CEO 30 years of diverse business experience in healthcare, information technology and finance including consulting, capital markets, private equity, and investments Chris

  19. Slide 19: Coeptis Scientific Advisory Board

    Slide 19: Coeptis Scientific Advisory Board

    19 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Scientific Advisory Board Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Evren Alici M.D., Ph.D. Arnika K. Wagner, Ph.D

  20. Slide 20: Coeptis Public Relations Contact

    Slide 20: Coeptis Public Relations Contact

    20 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Public Relations Contact: Daniel Kontoh - Boateng Tiberend Strategic Advisors [email protected] coeptistx.com

Source: SEC EDGAR · 8-K filed Dec 5, 2023

More decks from Coeptis Therapeutics Inc